Advertisement


Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Advertisement